Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jose A Covarrubias-Cobos
Effect of Tofacitinib on Patient-Reported Outcomes in Patients With Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors in the Phase III, Randomised Controlled Trial: OPAL Beyond
RMD Open
Rheumatology
Allergy
Immunology
Related publications
AB0794 Effect of Tofacitinib on Patient-Reported Outcomes in Patients With Active Psoriatic Arthritis: Results From Two Phase 3 Studies
Improved Patient-Reported Outcomes in Patients With Psoriatic Arthritis Treated With Abatacept: Results From a Phase 3 Trial
Arthritis Research & Therapy
Ixekizumab Is Efficacious When Used Alone or When Added to Conventional Synthetic Disease-Modifying Antirheumatic Drugs (cDMARDs) in Patients With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumour Necrosis Factor Inhibitors
RMD Open
Rheumatology
Allergy
Immunology
Adalimumab Improves Joint-Related and Skin-Related Functional Impairment in Patients With Psoriatic Arthritis: Patient-Reported Outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Impact of Tocilizumab Monotherapy on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis From Two Randomised Controlled Trials
RMD Open
Rheumatology
Allergy
Immunology
Randomized Trial of Tofacitinib in Active Ulcerative Colitis: Analysis of Efficacy Based on Patient-Reported Outcomes
BMC Gastroenterology
Medicine
Gastroenterology
Patient-Reported Outcomes for Tofacitinib With and Without Methotrexate, or Adalimumab With Methotrexate, in Rheumatoid Arthritis: A Phase IIIB/IV Trial
RMD Open
Rheumatology
Allergy
Immunology
Longterm (52-Week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients With Psoriatic Arthritis
Journal of Rheumatology
Rheumatology
Allergy
Immunology
Cost-Effectiveness of Combination Disease-Modifying Antirheumatics vs. Tumour Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: TACIT Trial
Arthritis Care and Research
Rheumatology
